Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Munich - Delayed Quote • EUR Medigene AG (MDG1.MU) Follow Compare 1.5500 0.0000 (0.00%) At close: March 11 at 8:00:08 AM GMT+1 Comparisons Indicators Technicals Corporate Events Line Candle Baseline Mountain Bar Step Baseline Delta HLC Wave Scatterplot Histogram Range Channel Colored Line Colored Mountain Colored Step Colored Bar Colored HLC Volume Candle Hollow Candle Step Mountain Vertex Line Vertex Step Vertex Mountain Vertex Baseline Delta Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for MDG1.MU 1D 5D -4.79% 1M 0.65% 3M 40.91% 6M -17.99% YTD 52.56% 1Y -45.69% 5Y -80.76% All -99.72% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours 1 day 1 week 1 month 3 months Recent News: MDG1.MU View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Medigene and EpimAb to develop T cell engagers for solid tumours Medigene and EpimAb Biotherapeutics Enter into a Co-Development Partnership for TCR-Guided T Cell Engagers Medigene AG Expands Patent Portfolio with Patent Grant for its JOVI Technology in the U.S. Medigene AG announces closing of its first SEPA tranche Medigene AG Announces KRAS G12V as First Target for TCR-guided T Cell Engagers Medigene Receives Milestone Payment from Regeneron Pharmaceuticals, Inc. Medigene AG Announces Refocus of Corporate Strategy and Organizational Realignment Medigene Presents Data on an Innovative IFN-γ Biosensor Technology at SITC 2024 Medigene Presents Latest Data on UniTope & TraCR Technology at PEGS and SITC 2024 Medigene Presents Unique Approach for Use of Optimal T Cell Receptors in TCR-Guided Modalities at Cell 2024 Can Medigene (ETR:MDG1) Afford To Invest In Growth?